Production and analysis of novel disulfide stabilised scFv-containing antibody formats
Ladataan...
suljettu
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
Lataukset5
Pysyvä osoite
Verkkojulkaisu
DOI
Tiivistelmä
Antibody engineering enables the production of antibody-based molecules with modified properties, and is a key tool in the development of modern therapeutics like monoclonal antibodies.
Full-length IgG molecules have favourable half-lives and effector functions, however their large size limits tissue penetration. In contrast, single-chain variable fragments (scFv) are smaller molecules formed solely by the antigen-binding domains of the antibody joined by a peptide linker. ScFv molecules have more efficient tissue penetration but tend to be unstable, have short half-lives and altered effector functions. This limitation can be addressed by linking scFv fragments to an Fc region, creating scFv-Fc fusion proteins, which retain similar characteristics to full-length IgGs such as longer half-lives, solubility, bivalent binding, and effector functions. Further engineering and stabilisation of scFv-Fc fusion proteins could yield new therapeutics that combine the favourable properties of full-length IgGs with enhanced tissue penetration and efficacy.
Previous research developed ultra-stable scFv fragments (ds-scFv) derived from trastuzumab by introducing a disulfide bridge in a novel position. Trastuzumab is a humanised IgG1 monoclonal antibody targeting the HER2 domain on tumour cells.
This is a proof-of-concept study which aims to produce and analyse the properties of two novel ds-scFv-containing trastuzumab antibody formats: (1) a bivalent construct (dsscFv-Fc), and (2) a tetravalent construct (dsscFv-Fc-dsscFv). Both constructs were expressed in mammalian cells, characterised and assessed for stability, binding and efficacy.
Results demonstrated increased thermostability in both constructs, compared to their non-disulfide stabilised analogue. Furthermore, showed to be high-affinity binders with a binding profile similar to trastuzumab. Lastly, the cell-based assays confirmed effective inhibition of proliferation in HER2 over-expressing tumour cells. These promising results encourage continued research into disulfide-stabilised scFv-Fc antibody formats for biomedical applications.